The Rationale for the Administering the Seviprotimut-L Vaccine to Patients with Melanoma
Craig L. Slingluff, MD, explains the rationale behind part B1 of the MAVIS study , which is investigating the use of the Seviprotimut-L vaccine in melanoma.
Craig L. Slingluff, MD, director of surgical oncology at the Emily Couric Clinical Cancer Center at the University of Virginia, explains the rationale behind part B1 of the MAVIS study , which is investigating the use of the Seviprotimut-L vaccine in melanoma.
There is a long history of trying to develop vaccines against melanoma. What is different about Seviprotimut-L, is that it was prepared from antigens shed by 3 human melanoma cell lines.
Part B1 of MAVIS is the first of three part in the phase III trial and is evaluating for the primary end point of relapse-free survival in patients with a high risk of recurrence after definitive surgical resection.
<< View more from the 2019 International Kidney Cancer Symposium>
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
